KRAS - Wikipedia KRAS acts as a molecular on off switch, using protein dynamics Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors, as well as other cell signaling receptors like c-Raf and PI 3-kinase
From Undruggable to Unstoppable: A New Cancer Cure Target Emerges The KRAS gene mutation, responsible for a quarter of all cancerous tumors, has met its match Thanks to UCSF research, a tiny “pocket” on a protein that signals the cells to grow and divide was discovered, leading to the world's first FDA-approved drugs that can now target and destroy these cancer cells
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic . . . Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of KRAS has been considered as being implausible to target for decades
Unpacking the diversity among KRAS mutants | Frederick National Laboratory The vast majority of patients harbor KRAS mutations and p53 alterations, a combination that yields poor outcomes and limited opportunities for tailored therapy 2-5 Though the most recent guidelines from the National Comprehensive Cancer Network advise molecular profiling for patients with advanced or metastatic pancreatic cancer, tumor features
The roles of KRAS in cancer metabolism, tumor microenvironment and . . . In this review, we aim to summarize current knowledge on KRAS-related metabolic alterations in cancer cells and explore the prevalence and significance of KRAS mutation in shaping the tumor microenvironment and influencing epigenetic modification via various molecular activities
Exploring KRAS: A precision approach in oncology - Merck KRAS is one of the most frequently mutated oncogenes found in cancer In healthy cells, KRAS serves as an on-off switch that regulates cell growth However, when the gene is mutated, KRAS can become stuck in the “on” position, causing uncontrolled cancer cell growth and proliferation
Targeting KRAS in cancer - Nature Medicine KRAS is a small membrane-bound GTP hydrolase protein that cycles between ‘on’ (GTP-loaded) and ‘off’ (GDP-unloaded) states This cycling between the ‘on’ and ‘off’ state depends on the activity
KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS MAPK pathway Learn about this gene and related health conditions